Cipla (CIPLA) — Announcement

Cipla received final USFDA approval for Paclitaxel Protein-bound Particles (Protein-bound Paclitaxel) on 10th April 2025. This AB-rated generic is a therapeutic equivalent to Bristol Myers Squibb's Abraxane® for treating metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma. The company plans to launch in the US during H1 FY2025-26, entering a significant oncology segment.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this announcement affect Cipla Limited's outlook?" "What did Cipla Limited announce on 11 April 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 11 April 2025

TECHM Tech Mahindra Limited Financial Results HAL Hindustan Aeronautics Limited Insider Trading TECHM Tech Mahindra Limited Financial Results ITC ITC Limited Corporate Action ONGC Oil & Natural Gas Corporation Limited Corporate Action RELIANCE Reliance Industries Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.